Proteograph Product Suite And Thermo Fisher Partnership Will Open Markets

Key Takeaways

• Strategic investments in commercial infrastructure and leadership aim to support revenue growth through increased productivity and sales effectiveness.
  
• Expanding partnerships and product innovation target enhanced adoption and customer value, potentially boosting sales and overall gross margins.
  
• Reliance on large contracts and macroeconomic challenges may restrict revenue growth and profitability, compounded by high expenses and prolonged sales ramp-up times.

Catalysts

A life sciences company, develops and commercializes products to decode the biology of the proteome.

• Seer anticipates expanding its customer base and enhancing access to its Proteograph Product Suite, which is expected to drive revenue growth as more institutions adopt their technology for various research applications.
  
• The company plans to drive product innovation and application expansion, which could enhance customer value propositions leading to an increase in consumable sales and service revenue, potentially boosting overall gross margins.
  
• Seer has made strategic investments in its commercial infrastructure, including doubling the size of its commercial team and onboarding new leadership in sales. This is expected to support revenue growth in 2025 as these new hires become more productive.
  
• The expanded partnership with Thermo Fisher is expected to enhance commercial reach and drive adoption of the Proteograph Product Suite, potentially increasing sales of instruments and consumables and thus impacting revenue positively.
  
• Continued validation of Seer's platform by generating more customer publications and compelling research is expected to drive broader adoption of its technology, paving the way for increased revenue from both product sales and related services.

Seer Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Seer's revenue will grow by 32.7% annually over the next 3 years.
• Analysts are not forecasting that Seer will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Seer's profit margin will increase from -611.1% to the average US Life Sciences industry of 12.9% in 3 years.
• If Seer's profit margin were to converge on the industry average, you could expect earnings to reach $4.3 million (and earnings per share of $0.09) by about April 2028, up from $-86.6 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 41.5x on those 2028 earnings, up from -1.4x today. This future PE is greater than the current PE for the US Life Sciences industry at 34.8x.
• Analysts expect the number of shares outstanding to decline by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.18%, as per the Simply Wall St company report.

Seer Future Earnings Per Share Growth

Risks

• The company experienced a decrease in revenue by 15% in 2024 compared to 2023, with lower product sales and no grant revenue recognized, impacting overall financial performance. This could affect future revenue growth and the company's ability to achieve profitability.
  
• The ongoing macroeconomic challenges and budget constraints, particularly in government and academic funding such as the NIH, introduce uncertainty that could restrict the purchasing capacity of Seer's primary customer base, potentially impacting future revenues.
  
• Seer's total operating expenses in 2024 were substantial at $107.2 million, and although they decreased compared to 2023, the high expenses contributed to a significant net loss of $86.6 million for the year. Sustained losses could put pressure on the company's financial stability and earnings.
  
• The company's reliance on a few large biopharma and government contracts exposes it to risks associated with budgetary fluctuations and funding uncertainties, which may lead to volatility in revenue streams and financial projections.
  
• The lengthy ramp-up time for new sales representatives (6 to 9 months) and the anticipated variability in gross margins suggest potential challenges in rapidly scaling revenue and maintaining consistent profit margins, impacting short-term earnings stability.

Valuation

• The analysts have a consensus price target of $3.0 for Seer based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $33.1 million, earnings will come to $4.3 million, and it would be trading on a PE ratio of 41.5x, assuming you use a discount rate of 7.2%.
• Given the current share price of $1.98, the analyst price target of $3.0 is 34.0% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.